How Much Does Crestor (Rosuvastatin) Cost in Michigan in 2026?

Michigan Retail Pricing: Brand vs. Generic Rosuvastatin

The price gap between brand-name Crestor and its generic equivalent is dramatic. AstraZeneca's list price for Crestor remains around $290 per month in 2026, a figure that has stayed relatively stable since the brand lost patent exclusivity. Generic rosuvastatin, by contrast, averages roughly $15 per month at Michigan retail pharmacies. That is a 95% reduction.

Several factors drive variability within those ranges. Pharmacy location matters. Large chain pharmacies in Detroit, Grand Rapids, and Ann Arbor often run competitive pricing programs for high-volume generics, sometimes pushing 30-day supplies of rosuvastatin below $10. Independent pharmacies in rural counties like Luce or Oscoda may price slightly higher due to lower purchasing volume, though the difference rarely exceeds a few dollars for a drug this widely dispensed.

Dose strength also affects cost, though less than patients typically expect. Rosuvastatin 5 mg and 10 mg tablets tend to price similarly at most Michigan pharmacies, while the 40 mg tablet can cost $2 to $5 more per month at cash-pay rates. The FDA-approved prescribing information for rosuvastatin lists approved doses from 5 mg to 40 mg daily, with 10 mg to 20 mg being the most commonly prescribed starting range [1].

A 2016 analysis in the Journal of the American Heart Association found that statin non-adherence costs the U.S. healthcare system an estimated $44.4 billion annually in avoidable cardiovascular events, with cost cited as a primary barrier to adherence [2]. At $15 per month, generic rosuvastatin in Michigan sits well below the threshold where cost typically disrupts adherence.

Michigan Medicaid Coverage for Rosuvastatin

Michigan Medicaid covers rosuvastatin, but the program requires prior authorization (PA). This means your prescriber must submit clinical documentation to the Michigan Department of Health and Human Services before the prescription will be approved for coverage.

The PA process typically takes 24 to 72 hours. Prescribers must demonstrate that the patient meets specific clinical criteria, which generally include a diagnosis of hyperlipidemia or documented ASCVD risk factors. For patients already stabilized on rosuvastatin before enrolling in Medicaid, the approval process tends to move faster because existing lab work and medication history satisfy the documentation requirements.

Michigan Healthy Michigan Plan enrollees follow the same PA pathway. The 2018 ACC/AHA Cholesterol Clinical Practice Guideline identifies four statin benefit groups, and Medicaid PA criteria in Michigan generally align with these categories: clinical ASCVD, severe hypercholesterolemia (LDL-C ≥190 mg/dL), diabetes in adults aged 40 to 75, and elevated 10-year ASCVD risk of 7.5% or higher [3]. Dr. Scott Grundy, lead author of the 2018 guideline, stated: "High-intensity statin therapy, including rosuvastatin 20 to 40 mg, remains the cornerstone of LDL-lowering treatment for patients at highest cardiovascular risk."

If your Medicaid PA is denied, Michigan law grants the right to appeal. Most denials result from incomplete documentation rather than clinical ineligibility, so working with your prescriber to resubmit with complete labs and risk scoring usually resolves the issue.

Compounded Rosuvastatin in Michigan: Legality and Access

Compounded rosuvastatin is legal in Michigan through licensed 503A compounding pharmacies. These pharmacies operate under the Federal Food, Drug, and Cosmetic Act as amended by the Drug Quality and Security Act of 2013, which established the regulatory framework for both 503A (patient-specific) and 503B (outsourcing facility) compounding [4].

Michigan's Board of Pharmacy licenses and inspects 503A pharmacies within the state. A compounding pharmacy operating under section 503A must compound rosuvastatin in response to a valid, patient-specific prescription. The compound cannot be an exact copy of a commercially available product unless the prescriber documents a clinical need for the compounded version (for example, a patient who requires a non-standard dose, a different delivery form, or removal of a specific inactive ingredient due to allergy).

Pricing for compounded rosuvastatin in Michigan varies by pharmacy but can be competitive with or even lower than generic retail pricing, particularly when a compounding pharmacy bundles the medication as part of a broader treatment protocol. Some telehealth platforms that operate in Michigan offer compounded rosuvastatin at no additional medication cost when included in a subscription care plan.

Patients considering compounded rosuvastatin should verify that the pharmacy holds a current Michigan 503A license and that the compound is prepared according to USP <795> standards for non-sterile compounding.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans available in Michigan place generic rosuvastatin on Tier 1 (preferred generic), which means the lowest copay tier. Typical Tier 1 copays at Michigan-based insurers range from $0 to $15 per month.

Blue Cross Blue Shield of Michigan (BCBSM), the state's dominant insurer, covers generic rosuvastatin on its standard formulary. Priority Health, another major Michigan plan operating primarily in West Michigan, also lists rosuvastatin as a preferred generic. HAP (Health Alliance Plan), based in Detroit, follows the same pattern.

Brand-name Crestor falls on Tier 3 (non-preferred brand) or higher at most Michigan plans. Copays at Tier 3 typically run $50 to $100 per month, and some plans require step therapy through the generic before approving brand coverage. Given that rosuvastatin is the same active molecule as Crestor at FDA-verified bioequivalence, there is rarely a clinical reason to insist on the brand.

The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the primary endpoint of major cardiovascular events by 44% compared to placebo (HR 0.56; 95% CI, 0.46 to 0.69; P<0.00001) in apparently healthy individuals with elevated high-sensitivity C-reactive protein [5]. This trial data, published in the New England Journal of Medicine, forms a core part of the clinical evidence base that insurers reference when placing rosuvastatin on their formularies. Dr. Paul Ridker, the JUPITER principal investigator, noted: "These data indicate that rosuvastatin significantly reduced the incidence of major cardiovascular events in a population not previously considered for statin therapy under existing guidelines."

For patients with Medicare Part D plans in Michigan, generic rosuvastatin typically falls in the lowest cost-sharing tier during the initial coverage phase. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare Part D out-of-pocket costs are capped at $2,000 annually, which provides additional protection for patients taking multiple medications alongside rosuvastatin [6].

Telehealth Prescribing of Rosuvastatin in Michigan

Michigan permits telehealth prescribing of rosuvastatin. The state updated its telemedicine regulations through Public Act 131 of 2020, which established parity between in-person and telehealth visits for prescribing authority. A Michigan-licensed physician, nurse practitioner, or physician assistant can evaluate a patient via synchronous video or audio-only telehealth and prescribe rosuvastatin if clinically appropriate.

The practical workflow for obtaining rosuvastatin via telehealth in Michigan looks like this: a patient completes an intake that includes cardiovascular risk factors, current medications, and recent lipid panel results. A licensed prescriber reviews the information, conducts a synchronous visit, and writes the prescription. The prescription routes to the patient's preferred Michigan pharmacy or a mail-order pharmacy licensed to dispense in the state.

Patients should have a lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) completed within the preceding 12 months before a telehealth statin consultation. If labs are not current, the prescriber will order them. Many Michigan-based lab networks, including those operated by Quest Diagnostics and Labcorp, offer walk-in lipid panels at locations throughout Metro Detroit, the I-96 corridor, and northern Michigan.

A meta-analysis published in The Lancet (Cholesterol Treatment Trialists' Collaboration, N=170,000 across 26 trials) found that each 1 mmol/L (approximately 39 mg/dL) reduction in LDL cholesterol with statin therapy reduces major vascular events by roughly 22% [7]. This consistent benefit across trial populations supports the appropriateness of telehealth-initiated statin therapy for eligible patients who face barriers to in-person visits.

How to Get the Lowest Price on Rosuvastatin in Michigan

Six strategies can reduce your out-of-pocket cost for rosuvastatin in Michigan.

Use the generic. This single step drops the price from approximately $290 per month to approximately $15 per month. Ask your prescriber to write for "rosuvastatin" rather than "Crestor," or confirm that your pharmacy automatically substitutes the generic (Michigan law permits generic substitution unless the prescriber writes "dispense as written").

Compare pharmacy prices. Cash-pay prices for generic rosuvastatin vary by $3 to $12 across Michigan pharmacies. Costco Wholesale pharmacies in Michigan (you do not need a membership to use the pharmacy) frequently offer among the lowest prices. Walmart and Meijer, both of which have large Michigan footprints, run competitive generic pricing programs.

Use discount cards and coupons. GoodRx, RxSaver, and similar platforms aggregate pharmacy pricing and offer coupons that can reduce the cash price below insurance copays in some cases. This is particularly useful for patients with high-deductible health plans who have not yet met their annual deductible.

Check manufacturer programs. AstraZeneca offers a savings card program for brand-name Crestor that can reduce copays for commercially insured patients. The card does not apply to government insurance (Medicaid, Medicare, Tricare). Eligible patients may pay as little as $3 per month for brand Crestor, though the program has annual caps and eligibility requirements that change periodically.

Apply for patient assistance. The AstraZeneca Patient Assistance Program (AZ&Me) provides free brand-name Crestor to uninsured or underinsured patients who meet income thresholds (generally at or below 300% of the federal poverty level). Michigan residents can apply through the program's website or by calling the AZ&Me helpline.

Ask about 90-day fills. Mail-order pharmacies and some Michigan retail pharmacies offer 90-day supplies at a reduced per-unit cost. For a maintenance medication like rosuvastatin taken daily and indefinitely, 90-day fills reduce both cost and the number of pharmacy trips.

Clinical Context: Why Rosuvastatin Pricing Matters for Michigan Patients

Michigan has one of the higher cardiovascular disease burden rates in the Midwest. According to CDC data on heart disease mortality, heart disease remains the leading cause of death in the state, and Michigan's age-adjusted heart disease death rate consistently exceeds the national average [8]. Statin underuse is a recognized contributor to preventable cardiovascular mortality.

The 2018 ACC/AHA guideline recommends high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) for patients with clinical ASCVD and for those with LDL-C ≥190 mg/dL [3]. Rosuvastatin is the most potent statin by milligram. At its 40 mg maximum dose, it reduces LDL-C by approximately 55% to 60%, according to data from the STELLAR trial published in the American Journal of Cardiology [9]. This potency advantage means that patients who do not reach LDL-C targets on other statins often respond to rosuvastatin.

Affordability directly affects whether patients start and continue statin therapy. A study in Annals of Internal Medicine found that even modest copay reductions for statins improved medication adherence and reduced rates of first cardiovascular events, with the largest effects seen in lower-income populations [10]. Given that Michigan's median household income falls below the national median, price sensitivity among Michigan statin users is real and clinically relevant.

For patients with a 10-year ASCVD risk between 5% and 7.5% (the so-called "borderline risk" group), the 2018 guideline suggests that risk-enhancing factors such as family history, metabolic syndrome, chronic kidney disease, or elevated high-sensitivity CRP may tip the decision toward statin initiation. The JUPITER trial specifically enrolled patients with hsCRP ≥2.0 mg/L and LDL-C <130 mg/dL, demonstrating benefit in a population that prior guidelines would not have treated [5]. This expanded indication is relevant for Michigan patients who fall into the borderline-risk category and wonder whether treatment is worthwhile.

Side Effects and Monitoring Considerations

Rosuvastatin is generally well tolerated. The most commonly reported side effects include myalgia (muscle pain without CK elevation, occurring in approximately 5% to 10% of patients), headache, nausea, and abdominal pain. Serious adverse effects such as rhabdomyolysis are rare, occurring at a rate of approximately 1.6 per 100,000 patient-years for rosuvastatin based on post-marketing surveillance data [11].

Michigan prescribers typically order a baseline lipid panel and hepatic function panel (ALT) before initiating rosuvastatin. Follow-up labs at 4 to 12 weeks assess LDL-C response and liver enzyme stability. Routine CK monitoring is not recommended unless the patient reports muscle symptoms.

The FDA prescribing information notes that rosuvastatin exposure increases in patients of Asian descent due to pharmacogenomic differences in ABCG2 transporter activity, and recommends a starting dose of 5 mg in this population [1]. Michigan has a significant Asian American population concentrated in Metro Detroit, Ann Arbor, and the Lansing area, making this dosing consideration clinically relevant for local prescribers.

Patients with an eGFR <30 mL/min/1.73 m² should not receive rosuvastatin doses above 10 mg daily. For patients on concurrent cyclosporine, the maximum rosuvastatin dose is 5 mg daily. These renal and drug-interaction dose limits apply regardless of where the rosuvastatin is dispensed.